Head-to-head evidence
picankibart vs tildrakizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 p19 · full Psoriasis pipeline
picankibart
Developed by Innovent Biologics
NCT05645627 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 500 participants. The sponsor reports that picankibart met its co-primary endpoints, with 80.3% of picankibart patients reaching PASI90 (at least 90% skin clearance) at week 16, compared with 2.0% of placebo patients, a highly significant difference.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
tildrakizumab · Ilumya
Marketed by Sun Pharmaceutical Industries
NCT01729754 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (N=1,090) in moderate-to-severe plaque psoriasis. The primary efficacy endpoints, PASI-75 and PGA clear/minimal at Week 12, were both statistically significant in favor of tildrakizumab 200 mg and 100 mg compared with placebo (p<0.001). The strong design and positive primary results provide high-quality evidence of treatment benefit.
Next expected readout: September 2028 · NCT05390515 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: picankibart's landscape · tildrakizumab's landscape